Medimaps Group S.A. has introduced its MDR-cleared next-generation TBS Osteo Advanced software in Europe, roughly a month after its U.S. debut.

The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care.

TBS Osteo is available through a subscription model, a flexible option providing customers with eligibility for software updates, new features, and support services. This approach ensures healthcare organizations have the latest innovations in osteoporosis care. Current TBS Osteo users can upgrade to the next generation version if they wish.

“The TBS Osteo next-generation software has been developed with busy radiology professionals in mind for a maximum of clinical output with a minimum of logistics. The software is seamlessly integrated into the clinical workflow and performed at time of DXA scan. This approach sets TBS Osteo apart from competition,” Univ. Prof. Dr. Didier Hans, CEO and co-founder of Medimaps Group. “TBS Osteo delivers within seconds a comprehensive report combining BMD and clinical factors, providing results beyond the standard of care. Adopted by many hospitals across the world, including in the U.S., DXA and TBS Osteo have become the gold standard to detect and monitor osteoporosis.”

Since its initial launch in 2012, TBS Osteo has been widely adopted globally to support osteoporosis assessment and management. The software is backed by over 1,400 peer-reviewed publications and endorsed by more than 30 national and international osteoporosis assessment and management guidelines.

In Europe, the software has received Medical Device Regulation (MDR) clearance and remains the only approved medical software for bone microarchitecture evaluation in clinical practice.

Osteoporosis is a condition that weakens bones and increases the risk of fractures. According to the International Osteoporosis Foundation, approximately 32 million Europeans aged 50 or over suffer from osteoporosis. The annual number of osteoporotic fractures across the European Union, Switzerland, and the United Kingdom is projected to rise from 4.33 million in 2019 to 5.34 million by 2034, an increase of more than 1 million fractures annually.¹ Despite the availability of effective treatments to reduce fracture risk, only one in five patients who experience an osteoporotic fracture are diagnosed or receive appropriate therapy.¹

Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management.​ The company provides healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment. Its passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with academics, clinicians, industry partners, and direct patient engagement. Headquartered in Geneva, Switzerland, Medimaps Group has offices in the United States and France. Its U.S. affiliate—Medimaps Group USA LLC—markets the company’s products and services.

Reference
¹ International Osteoporosis Foundation (IOF), https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-europe, Last accessed: June 24, 2025